Our findings show that EBV exhibits non-classical EBV latency II/III-like profiles in adenocarcinoma of prostate cancer based on the expression of EBNA-3B, EBNA-3A, EBNA-2, EBNA-1, LMP-2A, LMP-2, LMP-1, EBNA-LP, EBNA-3C, EBNA-2B, EBER-2, EBER-1, BZLF-1, and BHRF-1 (Table 3). This evidence concerns the gene PDLIM7 and prostate carcinoma.